Skip to main content
. 2017 Nov 20;130(22):2650–2660. doi: 10.4103/0366-6999.218019

Figure 3.

Figure 3

The survival benefit for postoperative transcatheter arterial chemoembolization (TACE) using the Shanghai Score for Cohort 1. Overall survival and recurrence-free survival in low-risk patients (a and b), moderate-risk patients (c and d), and high-risk patients (e and f); n = 4166 patients.